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Abstract 
Paraoxonase-1 (PON1) catalyzes the hydrolysis of organophosphorous (OP) nerve agents 
and has potential as a therapeutic agent for OP poisoning.  We are working on several aspects of 
PON1, such as understanding the catalytic residues involved in PON1, along with improving its 
stability and drug-like properties.  Specifically, I investigated the expression of human 
paraoxonase 1 (huPON1) in the periplasm, the space between the plasma membrane and the 
peptidoglycan wall of E. coli, using Maltose Binding Protein (MBP) as a solubility enhancer of 
our recombinant protein.  Most of the initial work was done using a chimeric (recombinant) 
rabbit homolog (rePON1 or G2E6) that expresses well in E. coli.  However, in order to utilize 
PON1 therapeutically, it likely needs to be in fully humanized form.  The major challenge here is 
the solubility and expression of human paraoxonase in bacterial systems such as E. coli.  MBP 
fusion was used to improve the solubility of huPON1 in E. coli.  The periplasmic expression is 
advantageous because it promotes disulfide formation; since huPON1 contains a disulfide bond, 
this strategy can potentially improve its soluble expression.  This strategy has proven useful for 
other difficult-to-express proteins with disulfide bonds, such as antibody fragments.  A well-
expressed, stable human protein within a bacterial system will help lead us closer to finding a 
sufficient treatment against organophosphate poisoning. 
 We also utilized the co-expression of molecular chaperones.  One of the principal 
problems of expressing protein in bacterial systems is the aggregation of proteins through their 
interactions among one another during their folding process.  This can result in protein 
degradation and improper native structure.  Just as periplasmic expression enhances proper 
protein folding, the application of chaperones sets out to catalyze protein folding within the 
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cytoplasm of E. coli. The co-expression of huPON1 with chaperone systems such as GroEL-
GroES and DnaK/DnaJ/GrpE could prove to be very useful for correct protein folding. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 4
Table of Contents 
Introduction………………………………………………………………………………………..6 
Organophosphate Background…………………………………………………………….6 
Therapeutic Agent…………………………………………………………………………6 
MBP Fusion……………………………………………………………………………….8 
Periplasmic Expression………………………………………………………....................9 
Chaperones……………………………………………………………………………….10 
Objectives………………………………………………………………………………………..14 
Expression and transport of G2E6 and huPON1 into periplasm………………………...14 
Increase solubility and activity of huPON1 in E. coli………...…………………………15 
Methods……..……………………………………………………………………………………15 
Creation of a periplasmic expression vector for G2E6 and huPON1……………………15 
Co-expression of huPON1 with multiple chaperone systems……………………………20 
Results and Discussion.………………………………………………………………………….22 
Expression and transport of G2E6 and huPON1 into periplasm………………………...22 
Increase of solubility and activity of huPON1 in E. coli through pKJE7……………….25 
Co-expression of pKJE7 with huPON1 variants………………...……………………...28 
Remarks………………………………………………………………………………………….31 
References………………………………………………………………………………………..32 
 
 
 
 5
Organophosphate Background 
Organophosphorous antiacetylcholinesterases (OP agents) such as Sarin, VX, VR, and 
paraoxon are highly toxic to humans.1,2 These nerve agents inhibit acetylcholinesterase at the 
synapse of neuromuscular junctions causing acetylcholine concentration to increase within the 
cleft.3 The buildup of acetylcholine leads to continuous firing of neurons and produces 
intramuscular convulsions.4 The known toxicity has proven lethal in chemical warfare by 
terrorist groups against civilian populations.2 There has been minimal success in rapid treatment 
to date.  All treatments for OP poisoning thus far are given post exposure.3 Atropine, an 
antagonist at the muscarinic acetylcholine receptor, is among the treatments.  Yet, reaching the 
OP agent before it arrives at the synapse could more efficient than post-exposure treatments.   
Our goal is to find a human protein capable of hydrolyzing organophosphates before and 
after exposure.  However, the ability to produce a catalytic protein in massive quantity along 
with having economic practicality is among the top challenges for creating a new treatment.5 
Furthermore, high catalytic activity, optimal half-life, immunotolerance, and the ability to turn 
over a diverse range of OPs are some of the required properties the therapeutic protein must 
possess.  Prokaryotic systems are ideal for manipulating specific recombinant genes with the 
over-expression of a target protein.  Specifically, E. coli has proven to be extremely versatile in 
the expression of recombinant human protein. 
Therapeutic Agent 
The target proteins known to have potential therapeutic activity against nerve agents are 
the human organophosphorous acid anhydride hydrolases (OPAHs), including human 
paraoxonase (huPON).6 PON1 and PON3 of the PON family can be found on high-density 
lipoprotein (HDL).7 Furthermore, the lactonase and anti-atherogenic activity of PON1 makes it 
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the protein of interest.1 The crystal structure has not yet been determined for huPON1, but it is 
available for recombinant PON1 and is described as a six-bladed β-propeller with each blade 
containing four strands.  There is also a site that is also thought to be involved in HDL binding. 
PON1 has three cysteine residues, with two of them (Cys42 and Cys353) forming a disulfide 
bridge.  Two calcium ions are located in the central part of the tunnel in the propeller. One is 
believed to play structural role and the other a catalytic one.3 
The catalytic residues involved in PON1 can help us understand several aspects of its 
mechanism, along with improving its stability and drug-like properties. However, in order to 
utilize PON1 therapeutically, it needs to be in fully humanized form.  The major challenge here 
is the solubility and expression of human paraoxonase in bacterial systems such as E. coli. 
Another challenge is creating a stable and well-folded protein (huPON1) capable of turning over 
organophosphates at a formidable rate.   
Recently, Clement Furlong and others have reported the first E. coli expression and 
purification of huPON1, along with other variants of PON1.8 However, their yields are very low.  
They have reported 5.5 mg of 90% pure protein from 12 L of fermentation.  Since cultures can 
be fermented to densities 10X as high as in a shake flask, that would correspond to 0.046 mg 
per liter of shake flask culture. This validates the challenge of expressing and purifying soluble 
human protein within a bacterial system. 
The approaches I have taken to combat these issues include using Maltose Binding 
Protein as a solubility enhancer tag, periplasmic expression to promote disulfide formation, and 
the utilization of chaperones to increase native folding of huPON1.  
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MBP Fusion 
 Maltose Binding Protein (MBP) will be employed as a solubility enhancer tag for 
improved solubility of rePON1 and huPON1.  MBP fusion has been shown to improve the 
solubility of many proteins that were insoluble in E. coli.9 Waugh and co-workers demonstrated 
this by directly comparing three different solubility tags; E. coli His-patch thioredoxin (TRX), 
Schistosoma japonicum glutathione S-transferase (GST), and E. coli maltose-binding protein 
(MBP).  MBP was fused to six different polypeptides (TIMP, p16, E6, CATΔ9, GFP, TEV) that 
are commonly insoluble in E. coli.  All fusion proteins were expressed at a high level in BL21 
(DE3) cells, revealing yields from 15% to 35% of total intracellular protein.  Based on 
comparisons, MBP fused proteins were shown to have a greater overall solubility than TRX and 
GST fused proteins.  The enhanced solubility of the formerly insoluble proteins is an indication it 
may be useful for increasing the problem of solubility of huPON1 in E. coli.  Furthermore, the 
MBP tag can be easily utilized along with other strategies such as expression within the 
periplasm of E. coli. 
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Figure 1. Comparison between protein solublility fusion tags.  MBP-fusions shows most 
improved protein solubility based on SDS-PAGE gels in each of six polypeptides.9   
Periplasmic Expression 
Periplasmic expression is advantageous because it contains a much less reducing 
environment in comparison to the cytoplasm.  Since huPON1 contains the disulfide bond 
between Cys43 and Cys353, this strategy can potentially improve the soluble expression of the 
protein by creating a more conducive environment for disulfide formation.  Periplasmic 
expression has proven useful for other difficult-to-express proteins with disulfide bonds, such as 
antibody fragments.10 For example, fragment antigen binding or single chain fragment variable is 
a disulfide-bonded protein with therapeutic importance.  The secretion of the fragment antigen 
binding chains into the oxidizing environment of the periplasm has produced more stable and 
native folded protein. Another example includes the purification of RNaseA fused with His6MBP 
containing the signal peptide for periplasmic export.11 As shown below, RNaseA shows large 
amounts of activity once exported and expressed in the periplasm.  This approach could support 
the formation of a stable huPON1. 
 
• = RNaseA expression in periplasm 
Ο = commercially available RNaseA 
▼ = RNaseA expression in cytoplasm 
Figure 2. Enzymatic activity of RnaseA fusion proteins. Expression in the periplasm 
showed the most change in absorbance and therefore the most activity.11  
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Chaperones 
Molecular chaperones assist and avert the misfolding of a protein due to adverse 
conditions within the cell.12 Early researchers believed inclusion bodies or protein aggregates to 
be unfolded protein and therefore were unaffected by proteases or chaperones.13 The over-
expression system in E. coli is more prone to produce protein aggregates and the accumulation of 
protein in the cytoplasm.  This can be toxic to the cell and thus there is less soluble protein.14 
However, Carrio and Villaverde prove that protein aggregation due to over-expression of 
targeted genes can be reversed in vivo.  Carrio and Villaverde did so by stopping protein 
synthesis of a β-galactosidase fusion protein, therefore preventing over-expression, and observed 
an increase in β-galactosidase activity and total soluble protein.8 Much research has been 
dedicated to finding ways of taking aggregated proteins and allowing them to re-fold into native 
conformation.  Recent approach is the co-expression of target recombinant genes with chaperone 
systems.15 Co-expression systems using chaperones have been confirmed in improving the yield 
of soluble protein in both bacterial and eukaryotic cells.  This is done by working against kinetic 
dead-end traps and helping the wrongly folded (aggregated) protein to go back and reach its 
thermodynamic minimum.16 Also, chaperones can help to stabilize interactive surfaces that are 
capable of interacting with other folding molecules.    
The use of chaperone systems including DnaJ/DnaK/GrpE and GroEL/GroES has been a 
hot topic of study.  Ario and Valeria de Marco confirm that co-transformation of different 
combinations of chaperones with target recombinant proteins in independent plasmids can 
increase the yield of soluble protein.15 The target recombinant proteins (GTR1/Xklp3B) exhibit 
increased solubility based on varying chaperone combinations according to Figure 3. 
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Figure 3.  Amount of soluble target protein GTR1/Xklp3B with various chaperone co-
expression from SDS-PAGE gel.  Each combination (K+J+E = DnaK/DnaJ/GrpE; ClpB = 
caseinolytic peptidase B; GroELS = GroEL/GroES) shows improved protein solubility in 
comparison to the control.15 
  The studies have recently moved to whether or not specific over-expressed chaperones 
can be applied in a general way to various human proteins.  One specific study focused on the 
use of DnaJ/DnaK/GrpE and GroEL/GroES chaperones and their effect on human protein 
kinases.17 They observed protein kinases unaffected by chaperone over-expression, protein 
kinases that were aggregated although showed increased solubility, and lastly kinases that were 
both aggregated and folded with increased solubility with chaperone over-expression.  This 
demonstrates that specific proteins were each affected differently in a case-specific way for each 
chaperone system. 
Another experiment specifically relates to a human protein having increased solubility in 
E.coli—and the analogous effect is sought for huPON1.18   Authors first tried expressing 
recombinant Endostatin (20 kDa), an anti-angiogenic protein and inhibitor of tumor growth, but 
nearly all was insoluble and formed inactive inclusion bodies.  The gels below show the 
insoluble protein on gel one (A), then, the solubilized protein on gel two (B) with the co-
expression of chaperones. 
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Figure 4.  Co-expression of chaperones with recombinant Endostatin separated into soluble 
(S) and insoluble (I) fractions.  Expressions done at 37 °C (A) and 16 °C  (B).  (B) shows 
improved soluble protein fraction expressed at 16 °C.18 
DnaK, DnaJ, and GrpE function together within the cell to catalyze the folding of various 
proteins.  DnaK has an N-terminal ATPase (44 kDa) domain and C-terminal peptide-bonding 
domain (27 kDa). It functions by binding and releasing proteins using ATP.19 It does so by 
recognizing exposed hydrophobic side chains.  Three E. coli J-proteins (DnaJ, DjlA and CbpA) 
interact with DnaK and accelerates its ATPase activity.  DnaJ (41 kDa) is the major J-protein and 
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is encoded on the same gene with DnaK.  DnaJ has four distinct domains—an N-terminal J-
domain that binds with DnaK, a glycine/phenylalanine domain, a zinc-finger domain to help with 
ATPase activity of DnaK and a C-terminal domain that helps recruit hydrophobic nascent chains 
to DnaK.  Finally, GrpE acts as a nucleotide exchange factor, inducing the release of ADP from 
DnaK.  Figure 5 shows the mechanism of the DnaK/DnaJ/GrpE chaperones. 
 
 
Figure 5.  Mechanism of DnaK/DnaJ/GrpE chaperone system.19 
 
 GroEL/GroES also function together by catalyzing and increasing the folding rate of 
protein.  In GroEL, two heptameric rings of identical 57 kDa subunits stacked back-to-back.  It 
consists of an equatorial domain with an ATP-binding site which is connected through an 
intermediate hinge-like domain to the apical domain. A cylinder is created from the hinge-like to 
the apical domain exposing hydrophobic residues toward the ring cavity.  GroES (10 kDa) is a 
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homoheptameric ring that is regulated by GroEL ATPase.  GroES cycles on and off of the 
GroEL cylinder.  Proteins up to 60 kDa can be encapsulated and can fold in the GroEL-GroES 
“cage.”  Figure 6 shows the mechanism of the GroEL/GroES chaperones. 
 
 
 
Figure 6. Mechanism of GroEL/GroES complex.19 
 
Objectives 
Expression and transport of G2E6 and huPON1 into periplasm 
The cysteines at positions 42 and 353 are the target of folding for the native huPON1 
structure in the periplasm.  The periplasm is situated between the inner cytoplasmic membrane 
and outer membrane or the space between the plasma membrane and the peptidoglycan wall in 
E. coli. Disulfide formation could be enhanced due to the oxidizing nature of the periplasm. 
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Formation of a protein containing disulfides within the cytoplasm is more difficult due to the 
reducing environment in E. coli.  Yet, rePON1 has demonstrated both activity and stability when 
expressed with E. coli, while huPON1 has produced large amounts of protein but was not soluble 
or active. Therefore, the possibility of transporting huPON1 synthesized in the reducing 
environment of the cytoplasm to the less reducing environment of the periplasm is a valuable 
strategy. 
Increase solubility and activity of huPON1 in E. coli 
 Recombinant proteins expressed within E.coli are often able to produce sufficient yields, 
but are still difficult to solubilize and keep a certain amount of activity from the protein to turn 
over substrate.9 In our case, huPON1 has reported high expression levels but with minimal 
solubility and no activity from purified protein.  If the end result is to produce a sufficient 
amount of the therapeutic protein, then, there must be a large enough production of soluble 
protein in order to properly vaccinate a patient exposed to OP toxins.  Additionally, the use of 
several strategies such as utilizing Maltose Binding Protein as a solubility tag along with 
bacterial chaperones could potentially help this problem.  Both strategies of maltose binding 
protein and molecular chaperones are capable of guiding the target protein in unfavorable 
conditions that could potentially keep the protein from forming into its native structure.  The 
ultimate goal is to provide a proficient, stabilizing environment for the protein to be able to fold 
into its native state. 
Methods 
Creation of a periplasmic expression vector for G2E6 and huPON1 
 In order to express our target protein within the periplasm, a vector containing a signal 
sequence is required for transportation of our target protein (G2E6, huPON1) to the periplasm of 
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E. coli.   The strategy was to use the periplasmic signal sequence from David Waugh’s pDEST-
periHisMBP vector.  pDEST-periHisMBP was utilized for the signal peptide MBP, His6-tag, and 
MBP sequence. The sequence was then inserted between the NdeI (344) and KpnI (458) sites in 
pET32b-G2E6 already containing recombinant PON1.  The thioredoxin (trx) solubility tag was 
therefore replaced by MBP in pET32-G2E6. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.  David Waugh’s periplasmic expression vector, pDEST-periHisMBP.11  
 
The signal sequence for the periplasm was extracted using PCR reactions.  Forward and reverse 
primers were created to use on pDEST-periHisMBP to facilitate the amplification of the signal 
peptide, His-tag, and MBP. 
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Table 1.  Primers for pDEST-periHisMBP signal sequence 
 
  Primers                                     Sequences in 5’ to 3’ 
Forward 
 
AATAAT AATCATATGAAAATAAAAACAGGTGCA 
                              NdeI                      Signal Sequence 
Reverse 
 
 
ATTATTATTGGTACCGCCCTGAAAATACAGGTTTTCCTCGAT 
                          KpnI                                     TEV 
CGTTTCTCGTTCAGCTTTTTTGTACAAACTTGTGATCGAA 
Finally, the 1200 base pair band of the amplified signal sequence was inserted into the pET32b-
G2E6 vector.  The signal sequence was ligated into pET32b-G2E6 at 16 °C overnight.  Next, the 
reaction was transformed into DH10B electrocompetent cells and the DNA was recovered 
through minipreps. The vector was expressed by transformation into BL21(DE3) to facilitate the 
production of G2E6 as an MBP-fusion protein.  The expression was done with 100 mL of 2YT 
media containing 100 μg/mL ampicillin and 0.11 g/L and grown at 37 °C.  Then, it was induced 
with isopropyl-β-D-thiogalactopyranoside (IPTG) at a 0.1 mM final concentration after the log 
phase was reached (A600 = 0.8) and placed at 30 °C for 4 hrs.  The cells were then pelleted by 
centrifugation and placed at –80 °C.  For purification of the fused protein, David Waugh’s 
osmotic shock procedure was employed.9 Frozen pellet was resuspended in 30 mM Tris-HCl (pH 
7.3) with 20% sucrose (80 mL of solution/gram of cell weight recovered).  Then, EDTA (1 mM 
final concentration) was added and cells were pelleted by centrifugation. Next, the pelleted cells 
were resuspended in ice-cold water (40 mL/gram pelleted).  This solution was mixed at 4 °C for 
10 minutes and cells were centrifuged once again. The osmotic shock fluid was considered the 
supernatant after this centrifugaton.  Ni-NTA agarose (0.3 mL of 50 percent) was equilibrated 
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with lysis buffer (50 mM Tris-HCl pH 8.0, 50 mM NaCl, 1 mM CaCl2, 10% Glycerol, 0.1% 
Tergitol) and used to capture and bind to our fusion protein. The buffers used in the purification 
of G2E6 are shown in Table 2. 
Table 2. Buffers for purification of G2E6 (periplasmic) 
All buffers contain 50mM Tris-HCl pH 8.0, 50mM NaCl, 1mM CaCl2, 10% Glycerol, 0.1%Tergitol 
Buffer Name Amount of Imidazole Amount Used 
        Wash 1 5 mM 5 mL 
        Wash 2 10 mM 5 mL 
                 Wash 3 25 mM 2 mL 
                Elution 1 125 mM 1 mL 
       Elution 2 125 mM 2 mL 
 
Purified G2E6 was tested for activity against the pesticide paraoxon.  Paraoxon hydrolysis 
activity was determined by using paraoxon (diethyl ρ-nitrophenyl phosphate) in 50 mM Tris, 1 
mM CaCl2 buffer at pH 7.4. Initial rates of ρ-nitrophenoxide formation (ε=18290 M-1cm-1) 
were  followed at 412 nm absorbance for 10 minutes.  The eluted protein, G2E6, was verified on 
a 12.5% SDS-PAGE gel. 
 Multiple experiments followed with the same type of expression only in a larger scale (1 
L) and varying purification conditions.  We also attempted a new technique for recovery of 
periplasmic proteins came from French and Moore.20 One of the first changes was the 
resuspension buffer consisting of 200 mM Tris-HCl pH 7.5 and 20% sucrose.  Another variation 
was the addition of lysozyme (500 μg/mL) to the resuspension buffer.  As a control, the pelleted 
cells (1 L culture expressions) were split into two—one resuspended in buffer containing 
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lysozyme and one without.  All other conditions were kept the same, including the wash and 
elution buffer contents (scaled up for 1 L culture). 
 The gene from huPON1 was cloned into the new construct, pET32-periHisMBP.  
huPON1 from pET32b-huPON1trx was amplified using PCR. Then, huPON1 was ligated  
Primer Sequence 5’to 3’ 
For 
huPON1
AATAATGGTACCGGTTCTTCTGGAGCC 
                      
                    KpnI 
 
ATGGCGAAGCTGATTGCG  
 
Rev 
huPON1
ATTATTCTCGAGTGCGGCCGCTTAGA 
                  XhoI 
GCTCAC 
pet32b-G2E6periHisMBPTev
7738 bp
KpnI - 1271 - G_GTAC'C
XhoI - 2371 - C'TCGA_G
Signal Sequence Per i MBP
G
2E6
AmpR
 
between the Kpn I and Xho I sites.  Once huPON1 was cloned into the construct, it was 
transformed into BL21(DE3) electrocompetent cells.  Each step was followed identically in 
regards to expression and purification of huPON1 as to G2E6.  The initial experiment used 1 L 
2YT culture expressions, and protein was purified using lysozyme resuspension buffer. Again, 
another non-lysozyme resuspension buffer was used on the other half of the frozen pellet.  
Purified huPON1 was tested for activity against the anti cholinesterase inhibitor, paraoxon.  
Paraoxon hydrolysis activity was done with the same conditions used above.  The eluted protein, 
huPON1, was verified on a 12.5% SDS-PAGE gel. Finally, the experiment was repeated to 
confirm the results.  
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  Co-expression of huPON1 with multiple chaperone systems 
 Plasmids containing molecular chaperones were obtained from Takara Bio Inc. (Japan) 
and include pG-KJE8, pGro7, pKJE7, pG-Tf2, and pTf16.  Plasmid details are included in table 
3.20 
                                    Table 3. Chaperone plasmids acquired from Takara Bio Inc. (Japan) 
 
(Trigger) 
Each plasmid containing the chaperones was co-transformed with huPON1 fused with 
thioredoxin into BL21(DE3) electrocompetent cells (0.5 μL of chaperone, 0.5 μL huPON1 from 
minipreps added to BL21(DE3).  The cells were recovered and plated on LB Amp/Cm.  100mL 
expressions in 2YT with 50 μg/mL amp and 20 μg/mL cm along with 0.5 mg/mL L-arabinose or 
1 ng/mL tetracycline added accordingly for each chaperone expression system.  The expressions 
were induced with isopropyl-β-D-thiogalactopyranoside (IPTG) at a 0.1 mM final concentration 
after the log phase was reached (0.8 absorbance at 600 nm) and placed at 30 °C for 4 hrs.  Cells 
were then pelleted by centrifugation and placed at –80°C.  Frozen pellets were then resuspended 
in 6mL lysis buffer (50 mM Tris-HCl pH 8.0, 50 mM NaCl, 1 mM CaCl2, 10% Glycerol, 0.1% 
Tergitol) with DTT (0.1 mM final concentration).  Then, the cells were passed through a syringe 
and sonicated.  Next, 10% tergitol (0.1% final concentration) was added and placed on a rotating 
mixer for 2.5 hours.  The cells were pelleted by centrifugation at 20,000 rpm for 30 minutes.  Ni-
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NTA agarose (0.5 mL of 50 percent) was equilibrated with lysis buffer and added to supernatant.  
The exact same procedure was followed from table 2 for purification.  Again, paraoxon activity 
assays were done with purified huPON1 co-expressed with each chaperone plasmid.  Purified 
huPON1 was confirmed on 12.5% SDS-PAGE gels. 
Initial experiments confirmed the chaperone system of choice to be pKJE7 
(DnaK/DnaJ/GrpE) for co-expression with huPON1.  We have also co-expressed huPON1 
variants that have increased solubility and activity with pKJE7.  Variants of huPON1 (obtained 
from M. Sarkar/G. Matic) included an N-terminal deletion of huPON1, HDL-huPON1 
(mutations within HDL binding site of huPON1), N-terminal deletion HDL-huPON1.  Each 
variant is tagged with MBP.  Wild-type huPON1 with MBP was also included with these 
experiments.  The same procedure was followed as above for co-expression in BL21(DE3).  
However, 1 L 2YT expressions were used as opposed to 100 mL.  Frozen pellets were then 
resuspended in 25 mL lysis buffer (50 mM Tris-HCl pH 8.0, 50 mM NaCl, 1 mM CaCl2, 10% 
Glycerol, 0.1% Tergitol) with DTT (0.5 mM final concentration).  Each of the following steps 
were identical to the procedure described in the first chaperone experiment.  For purification, 
table 3 shows the protocol used (M. Sarkar).  
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 Table 3. Purification Buffers for huPON1 variants co-expressed with KJE7 
Each buffer contains 20mM Tris-HCl pH 8.0 
 
Buffer Name NaCl CaCl2 Tween Imidazole Amount added 
Wash 1 50 mM 1 mM None 40 mM 20 mL 
Wash 2 1 M 1 mM None None 10 mL 
Wash 3 500 mM 1 mM None None 10 mL 
Wash 4 250 mM 1 mM None None 10 mL 
Wash 5 None 1 mM None None 1 mL 
Elution 1 
 
150 mM 
 
1 mM 
 
0.1% 
 
125 mM 
 
5 mL 
 
 
 
Paraoxon activity assays were done with purified huPON1 variants co-expressed with pKJE7.  
Purified huPON1 variants were confirmed on 12.5% SDS-PAGE gels. 
Results and Discussion 
Expression and transport of G2E6 and huPON1 into periplasm 
Figure 8 represents the 12.5% SDS-PAGE gel of G2E6 fusion protein (82 kDa) 
expression from the periplasmic vector.  All boxed bands on the following SDS-PAGE gels 
should represent the target protein based on the protein marker and previous experiments. 
Figures 9 and 10 are activity assays done against paraoxon.  Both the protein gel and activity 
assays were from the smaller scaled experiment (100 mL) that included lysozyme in the 
resuspension buffer.  The conclusion is that the MBP-G2E6 fusion protein was being expressed 
(seen on gel).  However, the activity assays demonstrate insufficient transport of the fusion 
protein because 80 to 90 percent of the active protein is present in the sonicated fraction.  There 
is minimal activity in the osmotic shock fluid representing the periplasmic protein.   
 22
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Figure 8. 12.5% SDS-PAGE gel showing MBP-G2E6 fusion protein (82 kDa) 
from periplasmic expression (100 mL).  Lane 1-8 in the following order are 
osmotic shock fluid, flow-through, wash one, wash two, wash three, elution one, 
and elution two.  The highlighted band is our protein, MBP-G2E6 (82 kDa) from 
elution one. The larger band beneath 52 kDa is thought to be MBP (42 kDa). 
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Figure 9. Paraoxon activity assay of sonicated fraction of MBP-G2E6 from periplasmic 
expression (100 mL).  MBP-G2E6 shows activity against paraoxon. 
 
 
 
 
 
 
 
Figure 10. Paraoxon activity assay of MBP-G2E6 from osmotic shock fluid in the 
periplasmic expression (100 mL).  The following symbols are OS-osmotic shock fluid, 
Lys-lysozyme, and OS+L- osmotic shock fluid with lysozyme.  The most active MBP-
G2E6 protein came from the recovery using osmotic shock with lysozyme treatment.  
Still, these elutions showed much less activity than the sonciated fraction. 
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Figure 11. 12.5% SDS-PAGE gel representing purified huPON1 from periplasmic 
expression (100 mL). Lane 1 is the marker. Lane 2 is the total fraction of protein. Lanes 3-5 
are part of the sonication and in order are the pelleted fraction, soluble fraction, and eluted 
fraction. Lanes 6-8 are part of the osmotic shock fluid and in order are the pellet, soluble 
fraction, and the eluted fraction.  As shown, there is a minimal amount of protein in the 
osmotic shock fluid in comparison to the sonicated fraction.  This again proves insufficient 
transportation of MBP-huPON1 to the periplasm. 
 
 
 
 
 
 
 
The periplasmic expressions of MBP-G2E6 and MBP-huPON1 showed there was protein being 
expressed within the cytoplasm.  However, whether or not the signal sequence was compatible or 
the protein was able to cross the membrane to the periplasm is unknown.   
Increase solubility and activity of huPON1 in E. coli through pKJE7 
The initial co-expression with the Takara chaperone systems confirmed that pKJE7 
(DnaK/DnaJ/GrpE) was benefiting the solubility of huPON1, resulting in enough protein to 
maintain activity against paraoxon.  Figure 12 shows pGro7, pKJE7, and pTf16 co-expressed 
with huPON1-trx in BL21(DE3).     
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Figure 12. 12.5% SDS-PAGE gel representing pGro7, pKJE7, and pTf-16 co-expressed with 
huPON1-trx (57 kDa). The first three lanes represent pelleted fraction, followed by lysate, and 
finally eluted protein (order of pGro7, pKJE7, and pTf16 for pelleted fraction- lanes 2-4, and 
same for lysates and elutions).  Eluted huPON1 (with pKJE7) is highlighted.  Note: huPON1-
trx (57 kDa) does run low on SDS-PAGE gels based from previous experiments (~50 kDa). 
Figure 13 shows there is activity against paraoxon when huPON1-trx co-expressed with 
pKJE7. Figure 14 confirms the initial results of active huPON1 co-expressed with pKJE7 against 
paraoxon (V.Shete).   pG-KJE8 and pG-Tf2 are not shown in a gel or activity assay because 
neither gave sufficient amounts of solubilized or active protein. 
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Figure 13. Paraoxon activity assay of huPON1-trx co-expressed with pGro7, pKJE7, and pTf16.  
Both pGro7 and pTf16 co-expressed with huPON1-trx do not show any activity.  However, 
huPON1-trx co-expressed with pKJE7 (DnaK, DnaJ, GrpE) does show activity against paraoxon. 
 
 
 
 
 
 
 
Figure 14. Paraoxon activity assay against huPON1-trx co-expressed with pKJE7.  This 
experiment confirmed activity against paraoxon. 
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           Co-expression of pKJE7 with huPON1 variants 
           The next step after selecting pKJE7 was to select variants of huPON1 to co-express with 
pKJE7.  The engineered huPON1 variants selected had already shown increased solubility in 
comparison to wild-type huPON1 (Magliery, Sarkar, Matic).  However, there had been a 
challenge in the purification steps of these variants.  The purification protocol from Table 3 
(M.Sarkar) was the newest and best procedure for variant purification.  Yet, the purified protein 
still contained apparent truncation products that had been eluted with it.  The gels below show 
some other bands, but the bands for N-terminal deletion huPON1 and N-terminal deletion HDL-
huPON1 have very distinct, clean bands.  Nonetheless, each purified protein exhibited cleaner 
bands with pKJE7 than without.  Figure 15 is presents purified huPON1-MBP with and without 
DnaK/DnaJ/GrpE for reference. Figure 16 shows HDL-huPON1 and N-terminal deletion HDL-
huPON1 co-expressed with pKJE7.  Figure 17 shows wild-type huPON1 and N-terminal deletion 
huPON1 co-expressed with pKJE7.  Figure 18 proves that all variants co-expressed with pKJE7 
proved to be active with N-teal deletion HDL-huPON1 being the most active.  
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Figure 16. 12.5% SDS-PAGE gel showing HDL-huPON1 and N-terminal deletion HDL-
huPON1 co-expressed with pKJE7. Lanes 1-5 are HDL-huPON1 and from left to right are 
pellet, supernatant, flow-through, wash 5, and elution 1. Lane 6 is the marker. Lanes 7-10 
are N-terminal deletion HDL-huPON1 and from left to right are pellet, supernatant, flow-
through and elution.  N-terminal deletion HDL-huPON1 co-expressed with pKJE7 shows a 
very clean band. 
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Figure 15.  SDS-PAGE gel showing reference band for huPON1-MBP (~82 kDa).  It is 
important to note huPON1-MBP does run low (~75-76 kDa).  All lanes represent 
purified protein from eluted fractions.  Lane 1 is origami B, lane 2 is DnaK/DnaJ/GrpE, 
lane 3 is huPON1-MBP, and lane 4 is huPON1-MBP co-expressed with 
DnaK/DnaJ/GrpE.  The lower band boxed in lane 4 is DnaJ (40 kDa). 
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Figure 17. 12.5% SDS-PAGE gel with wild-type huPON1 and N-terminal deletion huPON1 
co-expressed with pKJE7.  Lanes 1-4 are wild-type huPON1 and from left to right are pellet, 
supernatant, flow-through, and elution 1. Lane 5 is the marker. Lanes  6-10 are N-terminal 
deletion huPON1 and from left to right are pellet, supernatant, flow-through, elution 1 and 
wash 5.  Wild-type huPON1 co-expressed with pKJE7 shows a large amount of protein. 
Although, N-terminal deletion huPON1 shows less protein, it has a much cleaner band.
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Figure 18. Activity assay against paraoxon of huPON1 variants co-expressed with pKJE7.  
While all variants are active when co-expressed with pKJE7, N-terminal deletion HDL-
huPON1 shows the highest level of activity against paraoxon. 
KJE7/huPON1 variants against paraoxon  
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Remarks 
 
The periplasmic experiments did not successfully transport much of the target protein.  
The periplasmic expression vector was completed and its sequencing was confirmed.  There are 
several explanations that could explain why this problem arose.  First, it could have been the 
signal sequence being cleaved before the protein intermediate was able to reach the inner 
membrane.  Moreover, there are other possible signal sequences that could have replaced the 
initial one.  Another possible problem could have been that the sequence became attached or 
unable to cross over the membrane and reach the periplasm.  This could have been due to the 
HDL-binding site located on huPON1.   
All five chaperone plasmids from Takara Bio Inc. were tested and co-expressed with 
huPON1.  KJE7 co-expression has given active huPON1 along with cleaner more homogenous 
protein in comparison to non co-expressed huPON1.  We are now pursuing the expression of 
unfused huPON1 vector to see if co-expression with KJE7 is able to again produce an active 
huPON1 without MBP or trx fusions.  The cloning was done using ligation-independent 
cloning.22 Cloning has been completed and expression and purification will be done in the 
upcoming weeks. 
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